Literature DB >> 18493992

Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.

Rodney R Miles1, Martine Raphael, Keith McCarthy, Andrew Wotherspoon, Mark A Lones, Marie J Terrier-Lacombe, Catherine Patte, Mary Gerrard, Anne Auperin, Richard Sposto, Virginia Davenport, Mitchell S Cairo, Sherrie L Perkins.   

Abstract

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) makes up 10-20% of pediatric non-Hodgkin lymphoma, and these patients have a significantly better prognosis than adults with DLBCL. The difference in prognosis may be related to clinical, phenotypic, and/or biological differences between adult and pediatric DLBCL. In adult DLBCL, the germinal center (GC) phenotype is associated with a better prognosis than the activated B-cell (ABC) phenotype. However, a high proliferative index and expression of Bcl2 and c-Myc protein have all been associated with worse outcomes. While multiple studies have addressed the phenotype and expression patterns of adult DLBCL, relatively little is known about these biological variables in pediatric DLBCL. The goal of this study was to investigate the proliferative index, the relative frequencies of the GC and non-GC subtypes, and the expression of Bcl2 and c-Myc protein in a cohort of children with DLBCL treated in a uniform manner. PROCEDURE: We performed immunohistochemistry (IHC) for MIB1, CD10, Bcl6, MUM1, Bcl2, and c-Myc on DLBCL tissue from children treated uniformly in the FAB LMB96 trial (SFOP LMB96/CCG5961/UKCCSG/NHL 9600).
RESULTS: Compared to published adult DLBCL studies, pediatric DLBCL demonstrated moderate to high proliferation rates (83%), increased c-Myc protein expression (84%), decreased Bcl2 protein expression (28%), and an increased frequency of the GC phenotype (75%).
CONCLUSIONS: These findings suggest that there are significant biologic differences between pediatric and adult forms of DLBCL, which may contribute to the superior prognosis seen in the pediatric population relative to adult disease. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493992      PMCID: PMC2712231          DOI: 10.1002/pbc.21619

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  39 in total

1.  Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

Authors:  I S Lossos; C D Jones; R Warnke; Y Natkunam; H Kaizer; J L Zehnder; R Tibshirani; R Levy
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

2.  Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.

Authors:  Chung-Che Chang; Bal Kampalath; Christopher Schultz; Ellen Bunyi-Teopengco; Brent Logan; Camellia Eshoa; Ayse P Dincer; Sherrie L Perkins
Journal:  Arch Pathol Lab Med       Date:  2003-02       Impact factor: 5.534

3.  Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.

Authors:  B Saito; E Shiozawa; T Usui; H Nakashima; T Maeda; N Hattori; J Shimozuma; D Adachi; T Yamochi-Onizuka; M Takimoto; T Nakamaki; H Ota; S Tomoyasu
Journal:  Leukemia       Date:  2007-06-28       Impact factor: 11.528

Review 4.  B large-cell lymphoma in children and adolescents.

Authors:  Elizabeth Raetz; Sherrie Perkins; Virginia Davenport; Mitchell S Cairo
Journal:  Cancer Treat Rev       Date:  2003-04       Impact factor: 12.111

5.  Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas.

Authors:  C Kawasaki; K Ohshim; J Suzumiya; M Kanda; T Tsuchiya; K Tamura; M Kikuchi
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 7.  Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance.

Authors:  L de Leval; N L Harris
Journal:  Histopathology       Date:  2003-12       Impact factor: 5.087

8.  The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.

Authors:  Naoya Nakamura; Hirokazu Nakamine; Jun-Ichi Tamaru; Shigeo Nakamura; Tadashi Yoshino; Kouichi Ohshima; Masafumi Abe
Journal:  Mod Pathol       Date:  2002-07       Impact factor: 7.842

9.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

10.  Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.

Authors:  G Todeschini; S Secchi; E Morra; U Vitolo; E Orlandi; F Pasini; E Gallo; A Ambrosetti; C Tecchio; C Tarella; A Gabbas; A Gallamini; L Gargantini; M Pizzuti; G Fioritoni; L Gottin; G Rossi; M Lazzarino; F Menestrina; M Paulli; M Palestro; M G Cabras; F Di Vito; G Pizzolo
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  26 in total

1.  Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Authors:  Oussama Abla; Sheila Weitzman; Jean-Yves Blay; Brian Patrick O'Neill; Lauren E Abrey; Edward Neuwelt; Nancy D Doolittle; Joachim Baehring; Kamnesh Pradhan; S Eric Martin; Michael Guerrera; Shafqat Shah; Hervé Ghesquieres; Michael Silver; Rebecca A Betensky; Tracy Batchelor
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

2.  Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.

Authors:  Karen E Deffenbacher; Javeed Iqbal; Warren Sanger; Yulei Shen; Cynthia Lachel; Zhongfeng Liu; Yanyan Liu; Megan S Lim; Sherrie L Perkins; Kai Fu; Lynette Smith; James Lynch; Louis M Staudt; Lisa M Rimsza; Elaine Jaffe; Andreas Rosenwald; German K Ott; Jan Delabie; Elias Campo; Randy D Gascoyne; Mitchell S Cairo; Dennis D Weisenburger; Timothy C Greiner; Thomas G Gross; Wing C Chan
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

3.  Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.

Authors:  Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

Review 4.  Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Authors:  Justine M Kahn; Nmazuo W Ozuah; Kieron Dunleavy; Tara O Henderson; Kara Kelly; Ann LaCasce
Journal:  Blood Adv       Date:  2017-10-10

5.  Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.

Authors:  Mary Gerrard; Ian M Waxman; Richard Sposto; Anne Auperin; Sherrie L Perkins; Stanton Goldman; Lauren Harrison; Ross Pinkerton; Keith McCarthy; Martine Raphael; Catherine Patte; Mitchell S Cairo
Journal:  Blood       Date:  2012-11-13       Impact factor: 22.113

Review 6.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

Review 7.  Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.

Authors:  Catherine M Bollard; Megan S Lim; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 8.  Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Authors:  Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.

Authors:  Gabriela Gualco; Lawrence M Weiss; William J Harrington; Carlos E Bacchi
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

Review 10.  Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience.

Authors:  Jonas Lange; Birgit Burkhardt
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.